ScinoPharm Taiwan (stock code 1789), a company specializing in the development and manufacture of active pharmaceutical ingredients (APIs) and injectable formulations, announced that its 2018 consolidated annual revenue was NTD 3.524 billion, consolidated after-tax net profit was NTD 443 million, and after-tax earnings per share was NTD 0.56. The revenue and profitability have increased slightly from the previous year.

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2017. The consolidated revenue was NT$3.516 billion (US$120 million), after-tax net profits were NT$ 422 million (US$14.4 million). The after-tax earnings per share was NT$0.53 (US$0.018).

ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of delafloxacin active pharmaceutical ingredient (“API”) for Melinta’s Baxdela™,

International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) today announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments,

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2016.